LAB282 – accelerating drug discovery at Oxford

Oxford University, Oxford University Innovation, Oxford Sciences Innovation and Evotec announce a new partnership to advance the development of next-generation medicines arising from Oxford research.

Called ‘LAB282’, the partnership will provide a £13m fund, open now to biomedical researchers at Oxford, and an expert in residence in the University to aid the rapid translation of research outputs into new drug discovery and development programmes.

The ultimate goal of LAB282 is to accelerate the development of new treatments and cures for serious and debilitating disease. These will help patients live longer and better lives, reduce the burden on global healthcare systems, and promote economic growth.

See the full release on the University of Oxford site here, and the Evotec site here.

Simon Gray